Drawipas

Drawipas Brand names, Drawipas Analogs

Drawipas Brand Names Mixture

No information avaliable

Drawipas Chemical_Formula

C₁₁H₁₆N₂O

Drawipas RX_link

http://www.rxlist.com/cgi/generic3/tocainide.htm

Drawipas fda sheet

Drawipas msds (material safety sheet)

Drawipas Synthesis Reference

No information avaliable

Drawipas Molecular Weight

192.258 g/mol

Drawipas Melting Point

246-266 ^oC

Drawipas H₂O Solubility

1.07E+004 mg/L

Drawipas State

Solid

Drawipas LogP

1.308

Drawipas Dosage Forms

400 mg and 600 mg tablets for oral administration

Drawipas Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Drawipas Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Drawipas Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Drawipas side effects and Toxicity

The oral LD₅₀ of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Drawipas Patient Information

Drawipas Organisms Affected

Humans and other mammals